Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
122
-
Total 13F shares, excl. options
-
94.9M
-
Shares change
-
-1.54M
-
Total reported value, excl. options
-
$215M
-
Value change
-
-$4.44M
-
Put/Call ratio
-
0.13
-
Number of buys
-
63
-
Number of sells
-
-47
-
Price
-
$2.26
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2021
149 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2021.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 122 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 94.9M shares
of 236M outstanding shares and own 40.19% of the company stock.
Largest 10 shareholders include BlackRock Inc. (14.1M shares), VANGUARD GROUP INC (13.2M shares), STATE STREET CORP (11.7M shares), Nantahala Capital Management, LLC (4.92M shares), SATTER MANAGEMENT CO., L.P. (4.65M shares), MARSHALL WACE, LLP (4.48M shares), JPMORGAN CHASE & CO (4.43M shares), GEODE CAPITAL MANAGEMENT, LLC (3.21M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2.74M shares), and DIMENSIONAL FUND ADVISORS LP (2.59M shares).
This table shows the top 122 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.